ArticleBiomedicines2019
The Transformative Possibilities of the Microbiota and Mycobiota for Health, Disease, Aging, and Technological Innovation.
Article in Biomedicines, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- TUDCA Ameliorates Cognitive Impairment in APP/PS1 Mice by Modulating the Microbiota-Gut-Brain Axis.Current issues in molecular biology · 2026Article
- Targeting the Gut Microbiota in Pediatric Obesity: A Paradigm Shift in Prevention and Treatment? A Comprehensive Review.Nutrients · 2025Review
- Fungi in the Gut Microbiota: Interactions, Homeostasis, and Host Physiology.Microorganisms · 2025Review
- Gut mycobiome and neuropsychiatric disorders: insights and therapeutic potential.Frontiers in cellular neuroscience · 2024Review
- Gut microbiota in pathophysiology, diagnosis, and therapeutics of inflammatory bowel disease.Intestinal research · 2024Review
- Therapeutic Prospect of New Probiotics in Neurodegenerative Diseases.Microorganisms · 2023Review
- Natural Product Co-Metabolism and the Microbiota-Gut-Brain Axis in Age-Related Diseases.Life (Basel, Switzerland) · 2022Review
- Polyphenols and Small Phenolic Acids as Cellular Metabolic Regulators.Current issues in molecular biology · 2022Review
- Intestinal mycobiota in health and diseases: from a disrupted equilibrium to clinical opportunities.Microbiome · 2021Review
- Appetite Suppression and Interleukin 17 Receptor Signaling Activation of Colonic Mycobiota Dysbiosis Induced by High Temperature and High Humidity Conditions.Frontiers in cellular and infection microbiology · 2021Article
- Review on the Alteration of Gut Microbiota: The Role of HIV Infection and Old Age.AIDS research and human retroviruses · 2020Review
- Case report: nosocomial fungemia caused by Candida diddensiae.BMC infectious diseases · 2020Article
- The Role of the Microbiota-Gut-Brain Axis and Antibiotics in ALS and Neurodegenerative Diseases.Microorganisms · 2020Review
- The Microbiota-Gut-Brain Axis-Heart Shunt Part II: Prosaic Foods and the Brain-Heart Connection in Alzheimer Disease.Microorganisms · 2020Article
- Beyond Just Bacteria: Functional Biomes in the Gut Ecosystem Including Virome, Mycobiome, Archaeome and Helminths.Microorganisms · 2020Review
- The Impact of Gut Microbiota Disorders on the Blood-Brain Barrier.Infection and drug resistance · 2020Review
- The Other Obesity Epidemic-Of Drugs and Bugs.Frontiers in endocrinology · 2020Review
- Functional microbiome deficits associated with ageing: Chronological age threshold.Aging cell · 2020Article
- The role of the gut microbiome in mediating neurotoxic outcomes to PCB exposure.Neurotoxicology · 2019Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The gut microbiota is extremely important for the health of the host across its lifespan.Recent studies have elucidated connections between the gut microbiota and neurological diseaseand disorders such as depression, anxiety, Alzheimer's disease (AD), autism, and a host of otherbrain illnesses. Dysbiosis of the normal gut flora can have negative consequences for humans,especially throughout key periods during our lifespan as the gut microbes change with age in bothphenotype and number of bacterial species. Neurologic diseases, mental disorders, and euthymicstates are influenced by alterations in the metabolites produced by gut microbial milieu. Weintroduce a new concept, namely, the mycobiota and microbiota-gut-brain neuroendocrine axis anddiscuss co-metabolism with emphasis on means to influence or correct disruptions to normal gutflora throughout the lifespan from early development to old age. These changes involveinflammation and involve the permeability of barriers, such as the intestine blood barrier, the blood⁻brain barrier, and others. The mycobiota and microbiota⁻gut⁻brain axis offer new research horizonsand represents a great potential target for new therapeutics, including approaches based aroundinflammatory disruptive process, genetically engineered drug delivery systems, diseased cellculling "kill switches", phage-like therapies, medicinal chemistry, or microbial parabiosis to namea few.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.